Literature DB >> 19118701

I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30.

H Culver Boldt1, B Michele Melia, Judy C Liu, Sandra M Reynolds.   

Abstract

OBJECTIVES: (1) To summarize the protocol used for grading features of postradiation abnormalities from fundus photographs and fluorescein angiograms of patients enrolled in the Collaborative Ocular Melanoma Study (COMS); (2) to document the prevalence of features of interest in the posterior pole of these eyes during 8 years of follow-up; and (3) to investigate baseline patient, tumor, and treatment characteristics associated with posterior pole features.
DESIGN: Observational case series within a randomized, multicenter clinical trial. PARTICIPANTS: We evaluated 650 patients who were assigned to and received iodine-125 brachytherapy in the COMS for medium-sized tumors.
METHODS: Color fundus photographs and fluorescein angiograms were taken at baseline and 2, 5, and 8 years; 30 features were graded according to a standard protocol. MAIN OUTCOME MEASURES: Prevalence at selected time intervals of fundus photographic features associated with retinopathy and optic neuropathy.
RESULTS: The percentage of patients with >/=1 feature of interest was 49.2% at baseline, 84.4% at 2 years, 91.2% at 5 years, and 90.7% at 8 years. The most frequent findings across all follow-up examinations were macular microaneurysms (75.6% of examinations), macular angiographic leakage (75.1%), and optic disc hyperfluorescence (62.8%). The median number of features present increased significantly with each follow-up to a maximum of 7 features at 8 years. The prevalence of neovascularization of the disc at 5 years was 5.2%. The prevalence of optic neuropathy at 5 years was 27.4%. Prognostic factors for more prevalent and severe posterior pole abnormalities were diabetes, tumor location close to both optic nerve and foveal avascular zone, and greater dose of radiation to the foveola and optic nerve head.
CONCLUSIONS: The amount and severity of retinopathy and optic neuropathy after iodine-125 brachytherapy increased through 8 years of follow-up. Assessment of photographs and angiograms taken in accord with a standard protocol provided reliable estimates of rates of development of features of retinopathy and optic neuropathy in eyes treated using the COMS brachytherapy protocol. Our findings support earlier reports that tumor factors in addition to radiation treatment may contribute to posterior pole abnormalities. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118701      PMCID: PMC3202984          DOI: 10.1016/j.ophtha.2008.10.013

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  43 in total

1.  Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma.

Authors:  J C Hill; R Sealy; D Shackleton; C Stannard; J Korrubel; E Hering; C Loxton
Journal:  Br J Ophthalmol       Date:  1992-02       Impact factor: 4.638

2.  Proliferative radiation retinopathy.

Authors:  J L Kinyoun; B S Lawrence; W E Barlow
Journal:  Arch Ophthalmol       Date:  1996-09

3.  Plaque radiotherapy for juxtapapillary choroidal melanoma. Visual acuity and survival outcome.

Authors:  P De Potter; C L Shields; J A Shields; J R Cater; L W Brady
Journal:  Arch Ophthalmol       Date:  1996-11

4.  Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma.

Authors:  M W Wilson; J L Hungerford
Journal:  Ophthalmology       Date:  1999-08       Impact factor: 12.079

5.  Risk factors for radiation maculopathy and papillopathy after intraocular irradiation.

Authors:  E S Gragoudas; W Li; A M Lane; J Munzenrider; K M Egan
Journal:  Ophthalmology       Date:  1999-08       Impact factor: 12.079

6.  Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects.

Authors:  Robert Jones; Elizabeth Gore; William Mieler; Kevin Murray; Michael Gillin; Katherine Albano; Beth Erickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

7.  Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma.

Authors:  K Gündüz; C L Shields; J A Shields; J Cater; J E Freire; L W Brady
Journal:  Arch Ophthalmol       Date:  1999-05

8.  Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27.

Authors: 
Journal:  Ophthalmology       Date:  2007-03-06       Impact factor: 12.079

9.  Choroidal melanoma: I-125 plaque therapy.

Authors:  J L Bosworth; S Packer; M Rotman; T Ho; P T Finger
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

10.  Uveal melanoma radiation. 125I brachytherapy versus helium ion irradiation.

Authors:  D H Char; J R Castro; J M Quivey; T L Phillips; A R Irvine; R D Stone; S Kroll
Journal:  Ophthalmology       Date:  1989-12       Impact factor: 12.079

View more
  10 in total

Review 1.  Lasers for the treatment of intraocular tumors.

Authors:  Samuel K Houston; Charles C Wykoff; Audina M Berrocal; Ditte J Hess; Timothy G Murray
Journal:  Lasers Med Sci       Date:  2013-05       Impact factor: 3.161

Review 2.  Low-dose brachytherapy strategies to treat uveal melanoma: is less more?

Authors:  Patrick Oellers; Prithvi Mruthyunjaya
Journal:  Melanoma Manag       Date:  2016-02-17

Review 3.  Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned.

Authors:  Brittany E Powell; Kimberly J Chin; Paul T Finger
Journal:  Eye (Lond)       Date:  2022-08-16       Impact factor: 4.456

4.  An Infrared Dye-Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma.

Authors:  Rhonda C Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J Kang; Hans E Grossniklaus; Demetrios Vavvas; Stephen Monks; John R MacDougall; Elisabet de Los Pinos; John T Schiller
Journal:  Mol Cancer Ther       Date:  2017-12-14       Impact factor: 6.261

5.  Uveal melanoma.

Authors:  Vasilios P Papastefanou; Victoria M L Cohen
Journal:  J Skin Cancer       Date:  2011-06-30

Review 6.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22

7.  Reduced blood flow by laser speckle flowgraphy after 125I-plaque brachytherapy for uveal melanoma.

Authors:  Michelle R Tamplin; Jui-Kai Wang; Anthony H Vitale; Ryuya Hashimoto; Mona K Garvin; Elaine M Binkley; Daniel E Hyer; John M Buatti; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  BMC Ophthalmol       Date:  2022-06-28       Impact factor: 2.086

Review 8.  New insights into the prognosis of intraocular malignancy: Interventions for association mechanisms between cancer and diabetes.

Authors:  Lingwen Gu; Guofeng Ma; Cui Li; Jing Lin; Guiqiu Zhao
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

9.  Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas.

Authors:  Fariba Ghassemi; Shahab Sheibani; Mojtaba Arjmand; Hosein Poorbaygi; Emad Kouhestani; Siamak Sabour; Farhad Samiei; Akbar Beiki-Ardakani; Mahmood Jabarvand; Ali Sadeghi Tari
Journal:  Clin Ophthalmol       Date:  2020-02-04

10.  Temporal Relationship Between Visual Field, Retinal and Microvascular Pathology Following 125I-Plaque Brachytherapy for Uveal Melanoma.

Authors:  Michelle R Tamplin; Wenxiang Deng; Mona K Garvin; Elaine M Binkley; Daniel E Hyer; John M Buatti; Johannes Ledolter; H Culver Boldt; Randy H Kardon; Isabella M Grumbach
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-01-04       Impact factor: 4.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.